Trial Profile
Efficacy and safety of Niaspan [niacin] in South Asian stroke survivors: NIASTAR trial (Niaspan: Indo-Asian Stroke Patient Atherosclerotic Regression trial)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Aug 2019
Price :
$35
*
At a glance
- Drugs Niacin (Primary) ; Simvastatin (Primary)
- Indications Atherosclerosis; Stroke; Transient ischaemic attacks
- Focus Therapeutic Use
- Acronyms NIASTAR
- 05 Aug 2019 Status changed from active, no longer recruiting to completed.
- 22 Nov 2006 New trial record.